CL2017000782A1 - Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue - Google Patents
Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengueInfo
- Publication number
- CL2017000782A1 CL2017000782A1 CL2017000782A CL2017000782A CL2017000782A1 CL 2017000782 A1 CL2017000782 A1 CL 2017000782A1 CL 2017000782 A CL2017000782 A CL 2017000782A CL 2017000782 A CL2017000782 A CL 2017000782A CL 2017000782 A1 CL2017000782 A1 CL 2017000782A1
- Authority
- CL
- Chile
- Prior art keywords
- mono
- inhibitors
- dengue virus
- dengue
- virus replication
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title abstract 2
- 150000002475 indoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 208000001490 Dengue Diseases 0.000 abstract 2
- 206010012310 Dengue fever Diseases 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 208000025729 dengue disease Diseases 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE INDOL MONO- O DISUSTITUIDOS, MÉTODOS PARA PREVENIR O TRATAR INFECCIONES PAR EL VIRUS DEL DENGUE MEDIANTE EL USO DE DICHOS COMPUESTOS Y TAMBIÉN AL USO DE DICHOS COMPUESTOS COMO MEDICAMENTO, MÁS PREFERIBLEMENTE A SU USO COMO UN MEDICAMENTO PARA TRATA A PREVENIR INFECCIONES PAR EL VIRUS DEL DENGUE. LA PRESENTE INVENCIÓN SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS A PREPARACIONES A PARTIR DE COMBINACIÓN DE COMPUESTOS Y A COMPOSICIONES A PREPARADOS PARA USA COMO MEDICAMENTO, MAS PREFERIBLEMENTE PARA LA PREVENCIÓN A TRATAMIENTO DE INFECCIONES POR EL VIRUS DEL DENGUE. LA INVENCIÓN TAMBIÉN SE REFIERE A LOS PROCESOS DE PREPARACIÓN DE LOS COMPUESTOS.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14187374 | 2014-10-01 | ||
| EP15159164 | 2015-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000782A1 true CL2017000782A1 (es) | 2017-11-03 |
Family
ID=54199687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000782A CL2017000782A1 (es) | 2014-10-01 | 2017-03-31 | Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9944598B2 (es) |
| EP (1) | EP3201176B1 (es) |
| JP (1) | JP6732736B2 (es) |
| KR (1) | KR102478311B1 (es) |
| CN (1) | CN107001264B (es) |
| AU (1) | AU2015326930B2 (es) |
| BR (1) | BR112017006299A2 (es) |
| CA (1) | CA2959573A1 (es) |
| CL (1) | CL2017000782A1 (es) |
| CY (1) | CY1121874T1 (es) |
| DK (1) | DK3201176T3 (es) |
| EA (1) | EA032546B1 (es) |
| ES (1) | ES2714074T3 (es) |
| HR (1) | HRP20190199T1 (es) |
| HU (1) | HUE041888T2 (es) |
| IL (1) | IL251396A0 (es) |
| LT (1) | LT3201176T (es) |
| MA (1) | MA40768B1 (es) |
| ME (1) | ME03360B (es) |
| MX (1) | MX2017004299A (es) |
| PH (1) | PH12017500571A1 (es) |
| PL (1) | PL3201176T3 (es) |
| PT (1) | PT3201176T (es) |
| RS (1) | RS58461B1 (es) |
| SG (1) | SG11201702463YA (es) |
| SI (1) | SI3201176T1 (es) |
| SM (1) | SMT201900162T1 (es) |
| TW (1) | TWI681951B (es) |
| UA (1) | UA121119C2 (es) |
| UY (1) | UY36340A (es) |
| WO (1) | WO2016050841A1 (es) |
| ZA (1) | ZA201702301B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11053247B2 (en) | 2014-10-01 | 2021-07-06 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIA inhibitors |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| DK3201206T3 (da) | 2014-10-01 | 2019-12-16 | Merck Patent Gmbh | Borsyrederivater |
| PL3201177T3 (pl) * | 2014-10-01 | 2019-05-31 | Janssen Pharmaceuticals Inc | Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi |
| JOP20160086B1 (ar) * | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) * | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EA201892216A1 (ru) * | 2016-03-31 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге |
| US10646469B2 (en) | 2016-03-31 | 2020-05-12 | Janssen Pharmaceuticals, Inc. | Substituted indole derivatives as dengue viral replication inhibitors |
| JOP20170069B1 (ar) * | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN109069482B (zh) * | 2016-04-01 | 2022-04-05 | 杨森制药公司 | 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物 |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| TWI771420B (zh) * | 2017-05-22 | 2022-07-21 | 美商健生醫藥公司 | 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物（一） |
| AU2018274100B2 (en) | 2017-05-22 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| WO2024252254A1 (en) * | 2023-06-05 | 2024-12-12 | Zydus Lifesciences Limited | Novel compounds to treat viral infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012532102A (ja) * | 2009-06-30 | 2012-12-13 | シガ・テクノロジーズ・インコーポレーテッド | デングウイルス感染の治療法および予防法 |
| GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (ar) * | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) * | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
-
2015
- 2015-09-30 SI SI201530603T patent/SI3201176T1/sl unknown
- 2015-09-30 WO PCT/EP2015/072551 patent/WO2016050841A1/en not_active Ceased
- 2015-09-30 HU HUE15771136A patent/HUE041888T2/hu unknown
- 2015-09-30 CA CA2959573A patent/CA2959573A1/en not_active Abandoned
- 2015-09-30 EP EP15771136.7A patent/EP3201176B1/en active Active
- 2015-09-30 KR KR1020177011122A patent/KR102478311B1/ko active Active
- 2015-09-30 AU AU2015326930A patent/AU2015326930B2/en not_active Expired - Fee Related
- 2015-09-30 PT PT15771136T patent/PT3201176T/pt unknown
- 2015-09-30 ME MEP-2019-62A patent/ME03360B/me unknown
- 2015-09-30 SG SG11201702463YA patent/SG11201702463YA/en unknown
- 2015-09-30 PL PL15771136T patent/PL3201176T3/pl unknown
- 2015-09-30 BR BR112017006299-2A patent/BR112017006299A2/pt not_active Application Discontinuation
- 2015-09-30 EA EA201790758A patent/EA032546B1/ru not_active IP Right Cessation
- 2015-09-30 JP JP2017513061A patent/JP6732736B2/ja active Active
- 2015-09-30 CN CN201580053446.3A patent/CN107001264B/zh active Active
- 2015-09-30 ES ES15771136T patent/ES2714074T3/es active Active
- 2015-09-30 HR HRP20190199TT patent/HRP20190199T1/hr unknown
- 2015-09-30 MA MA40768A patent/MA40768B1/fr unknown
- 2015-09-30 TW TW104132008A patent/TWI681951B/zh not_active IP Right Cessation
- 2015-09-30 MX MX2017004299A patent/MX2017004299A/es unknown
- 2015-09-30 SM SM20190162T patent/SMT201900162T1/it unknown
- 2015-09-30 UA UAA201704215A patent/UA121119C2/uk unknown
- 2015-09-30 RS RS20190206A patent/RS58461B1/sr unknown
- 2015-09-30 LT LTEP15771136.7T patent/LT3201176T/lt unknown
- 2015-09-30 US US15/515,574 patent/US9944598B2/en active Active
- 2015-09-30 DK DK15771136.7T patent/DK3201176T3/en active
- 2015-10-01 UY UY0001036340A patent/UY36340A/es unknown
-
2017
- 2017-03-27 PH PH12017500571A patent/PH12017500571A1/en unknown
- 2017-03-27 IL IL251396A patent/IL251396A0/en unknown
- 2017-03-31 ZA ZA2017/02301A patent/ZA201702301B/en unknown
- 2017-03-31 CL CL2017000782A patent/CL2017000782A1/es unknown
-
2019
- 2019-03-01 CY CY20191100257T patent/CY1121874T1/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11053247B2 (en) | 2014-10-01 | 2021-07-06 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIA inhibitors |
| US12428421B2 (en) | 2014-10-01 | 2025-09-30 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIA inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000782A1 (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| UY36674A (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| CL2018002729A1 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| CL2018002758A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue. | |
| CO2018003471A2 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2018002784A1 (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| CL2019002745A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CO2018003369A2 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2019003309A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2018002718A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| CL2019002744A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2019003294A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. |